Pharma Focus Asia

Vaxxas Unveils Manufacturing Facility in Queensland, Australia


Vaxxas unveils world-class facility for needle-free vaccine patch production and commercial products in Queensland, Australia.

The new state-of-the-art biomedical manufacturing facility covers a total area of 5,500 square metres (60,000 square feet).

The facility aims to support the production of millions of high-density microarray patches (HD-MAPs) annually. These HD-MAPs will be utilised in future late-stage clinical trials and will eventually become the first commercial vaccine products.

The facility is equipped with two independent Good Manufacturing Practise (GMP) qualified aseptic cleanrooms. These cleanrooms ensure that the production processes adhere to strict quality and safety standards, which are crucial in the biomedical and pharmaceutical industries.

In addition to the aseptic cleanrooms, the facility also houses a medical device manufacturing space and a device assembly cleanroom. These areas are essential for the production and assembly of medical devices and components used in conjunction with the HD-MAPs.

This expanded capacity will not only accelerate the production of HD-MAPs but also create numerous skilled job opportunities in the local area. Currently, the facility employs 130 people, and increases this number to 200 employees in the coming years.


Name   Vaxxas
Type   New Construction

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Thermo Fisher Scientific - Rapid Mycoplasma TestingAsia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024ISPE Singapore Affiliate Conference & Exhibition 2024